The synthesis of novel matrix metalloproteinase inhibitors employing the Ireland-Claisen rearrangement
摘要:
Matrix metalloproteinase inhibitors of general formula (1) were synthesised by a route involving an Ireland-Claisen rearrangement which enables systematic modification of the substituent alpha to the hydroxamic acid. An analogue (12c) possessing an alpha-cyclopentyl group is a potent broad spectrum inhibitor that displays high and sustained blood levels following oral dosing in both the rat and marmoset ex-vivo bioassays. This compound and analogues are also potent inhibitors of TNF alpha release. (C) 1998 Elsevier Science Ltd. All rights reserved.
The synthesis of novel matrix metalloproteinase inhibitors employing the Ireland-Claisen rearrangement
摘要:
Matrix metalloproteinase inhibitors of general formula (1) were synthesised by a route involving an Ireland-Claisen rearrangement which enables systematic modification of the substituent alpha to the hydroxamic acid. An analogue (12c) possessing an alpha-cyclopentyl group is a potent broad spectrum inhibitor that displays high and sustained blood levels following oral dosing in both the rat and marmoset ex-vivo bioassays. This compound and analogues are also potent inhibitors of TNF alpha release. (C) 1998 Elsevier Science Ltd. All rights reserved.
The synthesis of novel matrix metalloproteinase inhibitors employing the Ireland-Claisen rearrangement
作者:Lisa M Pratt、R.Paul Beckett、Claire L Bellamy、Dominic J Corkill、Judy Cossins、Paul F Courtney、Stephen J Davies、Alan H Davidson、Alan H Drummond、Karen Helfrich、Christopher N Lewis、Matthew Mangan、Fionna M Martin、Karen Miller、Prakash Nayee、Michelle L Ricketts、Wayne Thomas、Richard S Todd、Mark Whittaker
DOI:10.1016/s0960-894x(98)00218-2
日期:1998.6
Matrix metalloproteinase inhibitors of general formula (1) were synthesised by a route involving an Ireland-Claisen rearrangement which enables systematic modification of the substituent alpha to the hydroxamic acid. An analogue (12c) possessing an alpha-cyclopentyl group is a potent broad spectrum inhibitor that displays high and sustained blood levels following oral dosing in both the rat and marmoset ex-vivo bioassays. This compound and analogues are also potent inhibitors of TNF alpha release. (C) 1998 Elsevier Science Ltd. All rights reserved.